Helsinn Group, based in Lugano, Switzerland, and MEI Pharma, with headquarters in San Diego, announced they were discontinuing their Phase III trial of pracinostat with azacytidine in acute myeloid leukemia (AML).

Sanofi and Regeneron halted a Phase III study of the checkpoint inhibitor Libtayo (cemiplimab) as a monotherapy treatment for advanced or metastatic non-small cell lung cancer due to early signs of significant improvement in overall survival.

Merck’s checkpoint inhibitor Keytruda (pembrolizumab) hit one of the coprimary endpoints early in the Phase III KEYNOTE-177 clinical trial for a highly mutating form of colorectal cancer.

AstraZeneca reported that high-level data analysis from the company’s Phase III CASPIAN trial demonstrated that Imfinzi (durvalumab) in combination with standard-of-care chemotherapies confirmed a clinically meaningful and sustained overall survival benefit in patients with extensive-stage small cell lung cancer treated in the first-line setting.

Two months after Pfizer and Astellas’ Xtandi won regulatory approval for a new indication in prostate cancer, the companies released positive new data in another type of prostate cancer.

Six months after winning approval from the U.S. Food and Drug Administration, Bayer announced that Nubeqa (darolutamide) posted stunning overall survival results by delaying the growth of tumors in men with non-metastatic castration-resistant prostate cancer.

Findings from the Phase III KEYNOTE-042 study show improvements in overall survival (OS), PFS and ORR in patients treated with Merck’s Keytruda (pembrolizumab) as a monotherapy.

Novartis said Kisqali helped women with advanced breast cancer after menopause live longer, adding to data the Swiss company hopes will help convince doctors to choose the drug over Pfizer’s blockbuster Ibrance.

Genentech announced positive data from the Phase III IMpower110 study evaluating Tecentriq as a first-line monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without ALK or EGFR mutations (wild-type; WT).

Treatment with Janssen’s Erleada plus androgen deprivation therapy (ADT) resulted in a 25 percent reduction in the risk of death compared with placebo plus ADT in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who were at high risk of developing metastases.